Adage Capital Partners
ANTX icon

Adage Capital Partners’s AN2 Therapeutics ANTX Stock Holding History

Adage Capital Partners’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.84M Hold
1,000,000
– – 0.01% 814
2026
Q1 		$3.42M Buy
+1,000,000
New +$2.06M 0.01% 802
2025
Q2 		– Sell
-1,000,000
Closed -$1.36M – 851
2025
Q1 		$1.36M Buy
1,000,000
+687,385
+220% +$865K ﹤0.01% 780
2024
Q4 		$431K Hold
312,615
– – ﹤0.01% 841
2024
Q3 		$334K Hold
312,615
– – ﹤0.01% 822
2024
Q2 		$672K Hold
312,615
– – ﹤0.01% 811
2024
Q1 		$1.02M Sell
312,615
-588,057
-65% -$6.4M ﹤0.01% 792
2023
Q4 		$18.5M Sell
900,672
-4,884
-0.5% -$81.7K 0.04% 444
2023
Q3 		$14.6M Buy
+905,556
New +$10.3M 0.03% 479

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners's ANTX Position: Q2 2026 in Review

Adage Capital Partners held its AN2 Therapeutics (ANTX) position steady in Q2 2026 at 1,000,000 shares worth $4.84M. The position accounts for 0.01% of the portfolio, ranked #814.

Adage Capital Partners first reported a position in ANTX in Q3 2023 and has held it in 9 quarters since. The position peaked at $18.5M in Q4 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Adage Capital Partners held 1,000,000 shares of AN2 Therapeutics worth $4.84M as of Q2 2026.
  • Adage Capital Partners left its AN2 Therapeutics share count unchanged in Q2 2026.
  • AN2 Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q2 2026, its #814 holding.
  • Adage Capital Partners first reported a position in AN2 Therapeutics in Q3 2023 and has held it in 9 quarters since.
  • Adage Capital Partners's AN2 Therapeutics position peaked at $18.5M in Q4 2023.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.